Research Topics
| Rogerio LilenbaumSummaryAffiliation: Mount Sinai Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Treatment of advanced non-small-cell lung cancer in special populationsRogerio C Lilenbaum
University of Miami, School of Medicine, Florida, USA
Oncology (Williston Park) 18:1321-5; discussion 1326, 1329-33. 2004..This article will review the data and discuss their clinical implications...- Treatment of patients with advanced lung cancer and poor performance statusRogerio C Lilenbaum
Thoracic Oncology Program, The Mount Sinai Comprehensive Cancer Center, Miami Beach, FL 33140, USA
Clin Lung Cancer 6:S71-4. 2004..When more specific data for this special population become available, it will hopefully lead to more consistent management and improved outcomes... - Chemotherapy in patients > or = 80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6Paul J Hesketh
Caritas St Elizabeth s Medical Center of Boston, Boston, Massachusetts 02135, USA
J Thorac Oncol 2:494-8. 2007.... - Prevalence of poor performance status in lung cancer patients: implications for researchRogerio C Lilenbaum
Thoracic Oncology Program, Mount Sinai Cancer Center, Miami Beach, Florida 33140, USA
J Thorac Oncol 3:125-9. 2008..However, despite its widespread use, little is known about the prevalence of poor PS in lung cancer patients, in relation to other cancers, based on the assessments of health care providers and patients... - Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancerRogerio Lilenbaum
The Mount Sinai CCOP, Miami Beach, Florida 33140, USA
J Thorac Oncol 3:511-5. 2008..We conducted a multicenter phase II study to evaluate the efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in patients with advanced non-small cell lung cancer (NSCLC)... - New horizons in chemotherapy: platforms for combinations in first-line advanced non-small cell lung cancerRogerio C Lilenbaum
Thoracic Oncology Program, Mount Sinai Cancer Center, Miami Beach, FL 33140, USA
J Thorac Oncol 3:S171-4. 2008.... - Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trialsRogerio Lilenbaum
Mount Sinai Cancer Center, Miami Beach, Florida 33140, USA
J Thorac Oncol 4:869-74. 2009..Data from two randomized phase III trials were analyzed to evaluate prognostic factors and treatment selection in the first-line management of advanced non-small cell lung cancer patients with performance status (PS) 2... - Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402Rogerio Lilenbaum
Mount Sinai Cancer Center, 4306 Alton Rd, Miami Beach, FL 33140, USA
J Clin Oncol 27:4487-91. 2009..A randomized phase II trial of two novel treatment strategies in the first-line management of advanced non-small-cell lung cancer patients with performance status (PS) 2... - Phase II trial of combined modality therapy with myeloid growth factor support in patients with locally advanced non-small cell lung cancerRogerio Lilenbaum
Mount Sinai Cancer Center Mount Sinai Clinical Community Oncology Program, Miami Beach, Florida 33140, USA
J Thorac Oncol 5:837-40. 2010..To evaluate the efficacy and safety of myeloid growth factors in patients with locally advanced non-small cell lung cancer treated with combined modality therapy (CMT)... - Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2Rogerio Lilenbaum
Mount Sinai Cancer Center 4306 Alton Road Miami Beach, FL 33140, USA
J Clin Oncol 26:863-9. 2008..A multicenter randomized phase II trial to evaluate two treatment strategies in the first-line management of advanced non-small-cell lung cancer (NSCLC) patients with a performance status (PS) of 2... - A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancerRogerio Lilenbaum
Mount Sinai Cancer Center, Miami Beach, FL 33140, USA
J Thorac Oncol 2:306-11. 2007..We conducted a multicenter randomized phase II trial to evaluate two schedules of single-agent docetaxel in the first-line treatment of elderly and performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC)... - Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancerRogerio Lilenbaum
Mount Sinai Cancer Center, Miami Beach, FL 33140, USA
J Clin Oncol 24:4825-32. 2006..This multicenter, phase II, randomized trial investigated efficacy and safety of irinotecan and docetaxel and irinotecan and gemcitabine, with or without CBX, in second-line treatment of NSCLC... - Combined modality therapy for limited-disease small cell lung cancerLuis Raez
Mount Sinai Comprehensive Cancer Center, 4306 Alton Road Miami Beach, FL 33140, USA
Curr Treat Options Oncol 6:69-74. 2005..Approximately 20% to 25% of patients with limited disease (LD)-SCLC can be cured with this aggressive approach. Newer treatment modalities are currently under investigation... - Management of advanced non-small-cell lung cancer in patients with a performance status of 2Rogerio Lilenbaum
Thoracic Oncology Program, Mount Sinai Comprehensive Cancer Center, Miami Beach, FL 33140 2840, USA
Clin Lung Cancer 5:209-13. 2004..Ongoing trials are in progress to further test the role of molecular-targeted agents alone or in combination with standard chemotherapeutic agents in this subset of patients... - Management of advanced non-small-cell lung cancer in elderly populationsRogerio Lilenbaum
Thoracic Oncology Program, The Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida 33140 2840, USA
Clin Lung Cancer 5:169-73. 2003..In elderly patients with less than optimal performance status or significant comorbid conditions, single-agent therapy may be more appropriate... - Molecular analysis-based treatment strategies for the management of non-small cell lung cancerHoward West
Thoracic Oncology Program, Swedish Cancer Institute, Seattle, WA 98104, USA
J Thorac Oncol 4:S1029-39; quiz S1041-2. 2009.... - The evolving role of cetuximab in non-small cell lung cancerRogerio C Lilenbaum
Thoracic Oncology Program, Mount Sinai Cancer Center, Miami Beach, Florida 33140, USA
Clin Cancer Res 12:4432s-4435s. 2006..Overall efficacy was slightly superior in the cetuximab arm and a phase III trial is currently ongoing to definitively determine the role of cetuximab in this setting... - Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730)Rogerio C Lilenbaum
The Mount Sinai Comprehensive Cancer Center, 4306 Alton Rd, Miami Beach, FL, USA
J Clin Oncol 23:190-6. 2005..We compared the efficacy of combination chemotherapy versus single-agent therapy in patients with advanced non-small-cell lung cancer... - Small cell lung cancer: past, present, and futureEstelamari Rodriguez
Mount Sinai Cancer Center, Miami Beach, FL 33140, USA
Curr Oncol Rep 12:327-34. 2010..The development of novel therapies for SCLC has been lagging behind, but completed clinical trials and ongoing investigations are helping us define what will be the best therapeutic targets for this disease... - New treatment strategies in patients with advanced non-small-cell lung cancer and performance status 2Estelamari Rodriguez
Mount Sinai Cancer Center, Miami Biach, FL 33140, USA
Clin Lung Cancer 9:326-30. 2008.... - Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapyThomas J Lynch
Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
J Thorac Oncol 3:S107-12. 2008..A CME activity based on this summary is also available at www.informedicalcme.com/cme... - Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agentsThomas J Lynch
Division of Hematology/Oncology, Massachusetts General Hospital, Boston 02114, and University of Colorado Cancer Center, Aurora, USA
Clin Cancer Res 12:4365s-4371s. 2006